Literature DB >> 1623906

A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin.

M Pitsiu1, E M Parker, L Aarons, B Holt, M Rowland.   

Abstract

We have studied the comparative abilities of the prothrombin time and factor VII clotting activity, measured using a chromogenic assay, to detect drug interactions with warfarin. Pharmacokinetic and pharmacodynamic data were collected from studies involving the single administration of 25 mg of warfarin in the absence and presence of fengabin, cimetidine, ranitidine, and enoxacin. Fengabin caused changes in both the pharmacokinetics and pharmacodynamics of warfarin, whereas cimetidine and enoxacin only caused changes in its pharmacokinetics. Ranitidine had no effect on either the pharmacokinetics or pharmacodynamics of warfarin. In general, factor VII clotting activity showed greater sensitivity but also greater variability than the prothrombin time to changes in clotting activity. Consequently, factor VII clotting activity did not have greater discriminatory power than the prothrombin time in detecting drug interactions involving warfarin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623906     DOI: 10.1007/bf00265930

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  The stereoselective interaction of warfarin and metronidazole in man.

Authors:  R A O'Reilly
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

Review 2.  Drug interactions with warfarin.

Authors:  M J Serlin; A M Breckenridge
Journal:  Drugs       Date:  1983-06       Impact factor: 9.546

3.  Coupled amidolytic assay for factor VII: its use with a clotting assay to determine the activity state of factor VII.

Authors:  U Seligsohn; B Osterud; S I Rapaport
Journal:  Blood       Date:  1978-11       Impact factor: 22.113

Review 4.  Carboxylated calcium-binding proteins and vitamin K.

Authors:  P M Gallop; J B Lian; P V Hauschka
Journal:  N Engl J Med       Date:  1980-06-26       Impact factor: 91.245

5.  Cimetidine potentiation of the hypoprothrombinemic effect of warfarin.

Authors:  B A Silver; W R Bell
Journal:  Ann Intern Med       Date:  1979-03       Impact factor: 25.391

6.  Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.

Authors:  S Toon; K J Hopkins; F M Garstang; L Aarons; A Sedman; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1987-07       Impact factor: 6.875

7.  Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations.

Authors:  C Banfield; R O'Reilly; E Chan; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

8.  Stereospecific fluorescence high-performance liquid chromatographic analysis of warfarin and its metabolites in plasma and urine.

Authors:  C Banfield; M Rowland
Journal:  J Pharm Sci       Date:  1984-10       Impact factor: 3.534

9.  Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.

Authors:  S Toon; K J Hopkins; F M Garstang; M Rowland
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

10.  Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.

Authors:  R A O'Reilly; C H Motley
Journal:  Ann Intern Med       Date:  1979-07       Impact factor: 25.391

View more
  1 in total

1.  Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjects.

Authors:  R A Smulders; M E Kuipers; W J J Krauwinkel
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.